Skip to content

Prevalence of Brief Suicidal Crisis in Psychiatric Settings

Prevalence of Brief Suicidal Crisis in Psychiatric Settings

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07740356
Acronym
RBSCP
Enrollment
150
Registered
2026-07-31
Start date
2026-09-01
Completion date
2026-12-31
Last updated
2026-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychiatric Disorder, Suicidal Crisis

Keywords

suicidal crisis

Brief summary

France is among the countries with one of the highest suicide rates in the world, far above those of its neighboring countries \[Wasserman et al., 2012\]. Suicide is the second leading cause of death among 15-24-year-olds, just after road traffic accidents, and the leading cause of death among 25-34-year-olds. Current models emphasize the variability of suicidal trajectories and the possible fluctuation in the duration of suicidal crises: for some individuals, the crisis evolves rapidly and explosively (brief), whereas for others, distress becomes more chronic, often in connection with underlying psychiatric disorders \[Stanley, Brodsky, and Monahan, 2023\]. In this context, the concept of a 'brief suicidal crisis' is an emerging one in psychiatry. It is characterized by an acute phase of psychological vulnerability, during which the main risk is progression to suicidal behavior, but it remains a temporary and reversible psychic crisis (lasting less than 24 hours). The crisis state is marked by a sudden inability to mobilize one's usual coping resources in the face of difficulties, making the individual highly vulnerable. Nevertheless, this concept has been little described, and a better assessment seems desirable, particularly in populations consulting a psychiatrist. Indeed, around 25% of people who die by suicide had consulted a psychiatrist in the month before their death \[Luoma et al., 2002\], yet few data are available on this topic. Primary objective is to assess the prevalence of brief suicidal crisis episodes (lasting less than 24 hours) over the past 12 months among patients attending outpatient psychiatric care and within a sample of patients from a population catchment area in the Clermont-Ferrand region.

Detailed description

Only one visit to estimate the 12-month prevalence of brief suicidal crises, defined as lasting less than 24 hours, among patients seen in outpatient psychiatric practice and in a population-based sample from the Clermont-Ferrand catchment area. Secondary objectives are to describe the study population and explore factors potentially associated with brief suicidal crises, including age and sex; to assess psychological pain during brief suicidal crises; to estimate the 12-month prevalence of suicidal crises lasting more than 24 hours; to assess psychological pain during suicidal crises lasting more than 24 hours.

Interventions

None listed

Sponsors

University Hospital, Clermont-Ferrand
Lead SponsorOTHER

Study design

Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Any adult patient consulting the psychiatrist in his/her office during the recruitment period, regardless of the reason for the consultation, and who has given consent to participate in this study.

Exclusion criteria

* Minor patients, or patients who refuse to participate in the study. * Patients who have already completed the self-administered questionnaires previously (e.g., a second consultation within the same week). * Patients unable to understand and complete the self-administered questionnaires (cognitive impairment, difficulty understanding French, etc.).

Design outcomes

Primary

MeasureTime frameDescription
Risk score of brief suicidal crisisDay 1Risque suicidaire de Ducher a (aRSD) scale score for brief suicidal crises. Minimum score 0 maximum score 10 . highter score mean worse outcome

Countries

France

Contacts

CONTACTPierre-Michel LLORCA, prof
pmllorca@chu-clermontferrand.fr33473752124
CONTACTingrid de Chazeron, PhD
idechazeron@chu-clermontferrand.fr33 473754580

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 1, 2026